[NBIX] Neurocrine Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 39.65 Change: 0.61 (1.56%)
Ext. hours: Change: 0 (0%)

chart NBIX

Refresh chart

Strongest Trends Summary For NBIX

NBIX is in the medium-term down -33% below S&P in 1 year. In the long-term up 66% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men?s and women?s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other con

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.83% ROE-12.96% ROI
Current Ratio22.19 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities275.28 M Cash From Investing Activities-170.01 M Cash From Operating Activities-4.22 M Gross Profit
Net Profit-23.99 M Operating Profit-25.32 M Total Assets511.2 M Total Current Assets389.42 M
Total Current Liabilities17.55 M Total Debt560 K Total Liabilities44.27 M Total Revenue
Technical Data
High 52 week125.85 Low 52 week68.32 Last close79.03 Last change-1.21%
RSI54.59 Average true range3.18 Beta1.39 Volume828.99 K
Simple moving average 20 days1.06% Simple moving average 50 days-4.52% Simple moving average 200 days-16.4%
Performance Data
Performance Week0.29% Performance Month-2.6% Performance Quart-6.27% Performance Half-20.57%
Performance Year-15.81% Performance Year-to-date10.67% Volatility daily2.49% Volatility weekly5.58%
Volatility monthly11.43% Volatility yearly39.6% Relative Volume252.57% Average Volume908.6 K
New High New Low

News

2019-06-18 08:03:56 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-06-13 08:04:47 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-06-11 16:01:00 | Neurocrine Biosciences to Present Data on INGREZZA® valbenazine and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders

2019-06-11 13:49:27 | Hedge Funds Are Dumping Neurocrine Biosciences, Inc. NBIX

2019-06-10 08:04:49 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-06-08 08:04:18 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-06-04 16:01:00 | Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference

2019-06-04 08:02:33 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-05-31 11:51:46 | Is Neurocrine Biosciences, Inc. NASDAQ:NBIX Trading At A 30% Discount?

2019-05-30 16:01:00 | Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference

2019-05-29 09:15:01 | Not Ready to Rally

2019-05-21 08:00:00 | AbbVie Launches ORILISSA™ elagolix 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

2019-05-20 08:00:00 | Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life

2019-05-16 16:01:00 | Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting

2019-05-08 09:15:01 | Trade Anxieties Return with a Vengeance

2019-05-07 16:01:00 | Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019

2019-05-07 08:02:32 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-05-06 08:00:00 | Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients

2019-05-05 09:05:00 | Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting

2019-05-05 09:00:00 | Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations

2019-04-30 17:36:26 | Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT

2019-04-30 16:01:00 | Neurocrine Biosciences to Present Data Analyses on INGREZZA® valbenazine and Opicapone at the 2019 American Academy of Neurology Annual Meeting

2019-04-30 10:35:02 | Neurocrine Biosciences Has Robust Late-Stage Pipeline

2019-04-30 09:01:20 | What Are Analysts Recommending for NBIX after Q1 Results?

2019-04-30 08:06:00 | The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

2019-04-29 22:38:43 | Neurocrine Biosciences Inc NBIX Q1 2019 Earnings Call Transcript

2019-04-29 16:15:23 | Neurocrine: 1Q Earnings Snapshot

2019-04-29 16:01:00 | Neurocrine Biosciences Reports First Quarter 2019 Financial Results

2019-04-26 06:10:23 | Analysts point to potential Biogen M&A options after Alzheimer's failure

2019-04-20 20:24:44 | Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. NBIX ?

2019-04-16 11:31:26 | Is Neurocrine Biosciences, Inc. NASDAQ:NBIX A Financially Sound Company?

2019-04-09 10:47:53 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-04-08 16:01:00 | Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results

2019-04-02 11:52:47 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-04-01 07:45:00 | Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences — Renewed Outlook, Key Drivers of Growth

2019-03-29 09:33:12 | Analysts Raise Neurocrine Biosciences’ Target Price in March

2019-03-28 16:15:00 | Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology

2019-03-26 08:25:02 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-03-23 10:02:00 | 2 Biotech Takeout Targets Perfect for Biogen

2019-03-20 10:43:28 | Sage Stock Pops on FDA Approval for Postpartum Depression Drug

2019-03-15 09:30:01 | CTLT or NBIX: Which Is the Better Value Stock Right Now?

2019-03-12 08:00:00 | Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia

2019-03-07 09:15:02 | Stocks Slide for Third Straight Day

2019-03-05 16:01:00 | Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

2019-03-05 08:01:53 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-03-01 12:33:17 | Why These 2 Biotech Stocks Might Be Next On The Takeover List

2019-02-28 11:56:07 | Why Neurocrine Biosciences, Inc. NASDAQ:NBIX Is An Attractive Investment To Consider

2019-02-22 11:31:07 | Voyager Therapeutics stock jumps on 2nd Parkinson's deal

2019-02-12 09:30:02 | CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

2019-02-08 08:05:10 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.